JP2019529574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529574A5 JP2019529574A5 JP2019538720A JP2019538720A JP2019529574A5 JP 2019529574 A5 JP2019529574 A5 JP 2019529574A5 JP 2019538720 A JP2019538720 A JP 2019538720A JP 2019538720 A JP2019538720 A JP 2019538720A JP 2019529574 A5 JP2019529574 A5 JP 2019529574A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- subject
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201662402004P | 2016-09-30 | 2016-09-30 | |
| US62/402,150 | 2016-09-30 | ||
| US62/402,004 | 2016-09-30 | ||
| PCT/EP2017/074849 WO2018060463A2 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529574A JP2019529574A (ja) | 2019-10-17 |
| JP2019529574A5 true JP2019529574A5 (https=) | 2020-11-12 |
| JP7062673B2 JP7062673B2 (ja) | 2022-05-06 |
Family
ID=60915459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538720A Active JP7062673B2 (ja) | 2016-09-30 | 2017-09-29 | 前立腺がんの治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (8) | US10449191B2 (https=) |
| EP (2) | EP3518932B1 (https=) |
| JP (1) | JP7062673B2 (https=) |
| CN (1) | CN110248661A (https=) |
| AU (2) | AU2017334035B2 (https=) |
| BR (1) | BR112019006228A2 (https=) |
| CA (1) | CA3038875A1 (https=) |
| DK (1) | DK3518932T3 (https=) |
| ES (1) | ES3002857T3 (https=) |
| FI (1) | FI3518932T3 (https=) |
| HR (1) | HRP20241740T1 (https=) |
| HU (1) | HUE070578T2 (https=) |
| IL (3) | IL308528A (https=) |
| LT (1) | LT3518932T (https=) |
| MA (1) | MA46361A (https=) |
| MX (2) | MX2019003733A (https=) |
| NZ (1) | NZ752918A (https=) |
| PL (1) | PL3518932T3 (https=) |
| PT (1) | PT3518932T (https=) |
| SI (1) | SI3518932T1 (https=) |
| WO (1) | WO2018060463A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2900675T3 (pl) | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| CN110248661A (zh) | 2016-09-30 | 2019-09-17 | 梦欧文科学有限责任公司 | 前列腺癌的治疗 |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| JP2022551316A (ja) * | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| WO2022087593A1 (en) * | 2020-10-20 | 2022-04-28 | Baylor College Of Medicine | Multiplex metabolic markers in plasma for early detection of african american prostrate cancer |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| WO2023152611A1 (en) * | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2710637B1 (fr) | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| KR20030005205A (ko) | 2000-02-29 | 2003-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 티에노피리미딘 유도체의 제조 방법 |
| WO2003057689A1 (en) | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| US7569570B2 (en) | 2002-01-30 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidines, process for preparing the same and use thereof |
| BRPI0307786B8 (pt) | 2002-02-26 | 2021-05-25 | Astrazeneca Ab | composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água |
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| AU2004257639B2 (en) | 2003-07-07 | 2011-01-06 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| KR20080041662A (ko) | 2005-07-22 | 2008-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 조기 배란 예방제 |
| EP2155194B1 (en) | 2007-04-06 | 2015-01-21 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| EP2329823A4 (en) | 2008-09-03 | 2013-04-03 | Takeda Pharmaceutical | PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY |
| PL2900675T3 (pl) | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| US10821152B2 (en) | 2014-08-26 | 2020-11-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| CA2978223A1 (en) | 2015-02-26 | 2016-09-01 | Takeda Pharmaceutical Company Limited | Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| US9949974B2 (en) | 2015-09-01 | 2018-04-24 | Abbvie Inc. | Methods of adminstering elagolix |
| US20180044977A1 (en) | 2016-08-12 | 2018-02-15 | Raynor Mfg. Co. | Rolling door construction for controlling air leakage |
| CN110248661A (zh) | 2016-09-30 | 2019-09-17 | 梦欧文科学有限责任公司 | 前列腺癌的治疗 |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
-
2017
- 2017-09-29 CN CN201780072970.4A patent/CN110248661A/zh active Pending
- 2017-09-29 AU AU2017334035A patent/AU2017334035B2/en active Active
- 2017-09-29 PT PT178230173T patent/PT3518932T/pt unknown
- 2017-09-29 EP EP17823017.3A patent/EP3518932B1/en active Active
- 2017-09-29 JP JP2019538720A patent/JP7062673B2/ja active Active
- 2017-09-29 CA CA3038875A patent/CA3038875A1/en active Pending
- 2017-09-29 FI FIEP17823017.3T patent/FI3518932T3/fi active
- 2017-09-29 IL IL308528A patent/IL308528A/en unknown
- 2017-09-29 BR BR112019006228A patent/BR112019006228A2/pt not_active Application Discontinuation
- 2017-09-29 MX MX2019003733A patent/MX2019003733A/es unknown
- 2017-09-29 IL IL300071A patent/IL300071A/en unknown
- 2017-09-29 PL PL17823017.3T patent/PL3518932T3/pl unknown
- 2017-09-29 HR HRP20241740TT patent/HRP20241740T1/hr unknown
- 2017-09-29 NZ NZ752918A patent/NZ752918A/en unknown
- 2017-09-29 SI SI201731574T patent/SI3518932T1/sl unknown
- 2017-09-29 LT LTEPPCT/EP2017/074849T patent/LT3518932T/lt unknown
- 2017-09-29 DK DK17823017.3T patent/DK3518932T3/da active
- 2017-09-29 WO PCT/EP2017/074849 patent/WO2018060463A2/en not_active Ceased
- 2017-09-29 ES ES17823017T patent/ES3002857T3/es active Active
- 2017-09-29 EP EP24212224.0A patent/EP4520398A3/en active Pending
- 2017-09-29 MA MA046361A patent/MA46361A/fr unknown
- 2017-09-29 HU HUE17823017A patent/HUE070578T2/hu unknown
-
2019
- 2019-03-28 IL IL265697A patent/IL265697B2/en unknown
- 2019-03-29 MX MX2023001468A patent/MX2023001468A/es unknown
- 2019-03-29 US US16/369,729 patent/US10449191B2/en active Active
- 2019-09-06 US US16/563,161 patent/US10786501B2/en active Active
-
2020
- 2020-08-20 US US16/998,900 patent/US11583526B2/en active Active
-
2022
- 2022-07-15 US US17/866,203 patent/US12097198B2/en active Active
-
2023
- 2023-02-22 AU AU2023201047A patent/AU2023201047B2/en active Active
-
2024
- 2024-06-28 US US18/758,904 patent/US12144809B1/en active Active
- 2024-11-05 US US18/937,891 patent/US12336990B2/en active Active
- 2024-11-25 US US18/959,460 patent/US20250082632A1/en active Pending
-
2025
- 2025-07-09 US US19/264,673 patent/US20250332166A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529574A5 (https=) | ||
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| CN103945849B (zh) | 癌症的联合治疗 | |
| JP2013501731A5 (https=) | ||
| JP2020529996A5 (https=) | ||
| US20110124617A1 (en) | Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent | |
| JP2020079320A (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| TW200942235A (en) | Dosing regimen for a selective S1P1 receptor agonist | |
| JP2019505585A (ja) | ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法 | |
| JP2015531373A5 (https=) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2010522714A (ja) | 新規な医薬組成物 | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| AU2002310788B2 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| CN1262622A (zh) | 调节人性反应的联合治疗 | |
| CN107072969B (zh) | 使用顺式氯米芬治疗雄激素剥夺疗法诱导的热潮红和骨丢失 | |
| JP2023549196A5 (https=) | ||
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| JP2022543679A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2014522414A5 (https=) | ||
| RU2017134553A (ru) | Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов, и их применение | |
| JP2005513167A5 (https=) |